TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07785180: Retrospective Study of Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated With Chemotherapy Agents

Sponsor: Stemline Therapeutics, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07785180 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07785180 Rescue Dossier →